What does epigenetics mean to CLL?
REMoDL-B clinical trial: results presented at ASH 2015
Double hit lymphoma: a challenge for lymphoma experts
Highlights from the International Workshop of the German CLL Study Group
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele